Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?

Table 3 Laboratory characteristics of patient and control groups, mean ± SD

Variables	MASLD with DM (n = 50)	MASLD without DM (n = 50)	Control group (n = 50)	P value
Hb (g/dL)	12.03 ± 1.23	12.09 ± 2.87	12.45 ± 2.42	0.542
Platelets (103/uL)	290.10 ± 55.90	312.98 ± 46.99	302.08 ± 67.54	0.206
Leucocytes (103/uL)	6.67 ± 2.01	7.617 ± 2.35	7.01 ± 2.98	0.105
PLR	208.45 ± 45.78	201.21 ± 55.09	134.29 ± 32.90	< 0.001
NLR	2.39 ± 0.98	2.22 ± 0.76	1.20 ± 0.50	< 0.001
FBS (mg/dL)	228.17 ± 40.45	158.22 ± 39.10	148.76 ± 54.56	< 0.001
Glycosylated Hb (%)	7.67 ± 0.27	5.17 ± 0.24	5.20 ± 0.36	< 0.001
INR	1.02 ± 0.01	1.01 ± 0.01	1.01 ± 0.01	0.395
Sodium (mmol/L)	134 ± 0.19	133.5 ± 0.18	133.10 ± 0.04	0.085
Potassium (mmol/L)	3.98 ± 0.57	4.24 ± 0.55	4.01 ±0.30	0.212
Cholesterol (mg/dL)	221.09 ± 22.05	210.45 ± 18.98	154.23 ± 34.09	< 0.001
Triglycerides (mg/dL)	134.30 ± 29.76	114.10 ± 21.10	101.22 ± 19.14	< 0.001
LDL (mg/dL)	128.19 ± 38.19	123.11 ± 33.47	98.10 ± 29.50	0.011
HDL (mg/dL)	47.80 ± 4.59	48.79 ± 4.12	50.56 ± 5.42	0.761
AST (u/L)	89.18 ± 15.43	79.18 ± 10.45	22.70 ± 3.87	< 0.001
ALT (u/L)	78.11 ± 6.66	68.11 ± 7.69	27.56 ± 5.10	< 0.001
Albumin (mg/dL)	3.79 ± 0.59	3.80 ± 0.36	3.98 ± 0.40	0.198
Bilirubin (mg/dL)	1.09 ± 0.12	1.18 ± 0.18	0.99 ± 0.11	0.464
CRP (mg/dL)	2.45 ± 2.45	2.12 ± 0.68	2 ± 1.20	0.173
ESR (mL/hour)	15.28 ± 3.01	11.28 ± 2.10	6.70 ± 2.18	0.472
HOMA-IR	2.89 ± 1.21	1.34 ± 0.87	1.31 ± 0.23	< 0.001

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CRP: C-reactive protein; DM: Diabetes mellitus; ESR: Erythrocyte sedimentation rate; FBS: Fasting blood sugar; Hb: Hemoglobin; HDL: High density lipoproteins; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; INR: International normalized ratio; LDL: Low density lipoproteins; MASLD: Metabolic dysfunction-associated steatotic liver disease; NLR: Neutrophil/Lymphocyte ratio; PLR: Platelets/Lymphocyte ratio.